Skincoach
References from this period: 4 LinkedIn recommendations, full text. They vouch for the role, not for any one claim.
Proof points: 2
| Role | Product | Situation | Task | Action | Result | Year | Skills |
|---|---|---|---|---|---|---|---|
| PM/GM at LEO Innovation Lab | Skincoach Skincoach, a patient-support app for terminally ill cancer patients, built in partnership with Amgen | Amgen, one of the world's largest biotech companies and a leading maker of immunotherapy treatments, wanted to help patients manage the skin reactions that come with treatment. Those reactions affect quality of life and, in some cases, whether a patient can stay on treatment. Nothing existed for the time between oncologist appointments. | Build a product for this audience under strict regulatory and ethical constraints, and agree a partnership model with Amgen that neither company had used before. | Interviewed terminally ill patients and worked with oncologists to reimagine care between appointments. Every decision intentional and judged with sensitivity: no moving fast and breaking things. Dynamically spliced video to simulate personalised dermatology consultations, designed for simplicity and trust. Negotiated a new partnership model with Amgen that challenged convention. | Full product lifecycle in 8 months, on time and on budget. Live closed pilot in Spain and France. The partnership model was later adopted by Amgen's core business as an exemplar for innovation partnerships. | Feb 2018 - Oct 2018 | regulated, healthcare, patients, discovery, ways of working, growth, launch, domains, international, stakeholders, partnerships, budget |
| PM/GM at LEO Innovation Lab | Amgen partnership model Innovation partnership between LEO Innovation Lab and Amgen for Skincoach | Partnerships operated as mercenaries not missionaries. The standard contracting process was delivery to be completed (output), not outcomes. | Negotiate a partnership model that allowed building and piloting inside the constraints of two regulated companies. | Managed stakeholders on both sides and negotiated a new partnership model and ways of working. It challenged convention at the time. | The contract model and ways of working were later adopted by Amgen's core business as an exemplar for innovation partnerships. Tom led in-market discovery and delivery under it. | Feb 2018 - Oct 2018 | regulated, healthcare, patients, discovery, ways of working, growth, launch, domains, international, stakeholders, partnerships, budget |
Tell me about Skincoach
source: Tom's own account
PM/GM at LEO Innovation Lab (Feb 2018 - Oct 2018), building a patient-support app for terminally ill cancer patients in partnership with Amgen.
This was some of the most meaningful work I've done. The app was designed to help patients manage side effects from their treatment.
It was a really difficult project, intense and emotionally demanding. I remember sitting at my desk, headphones on, listening to patient interviews and crying. It made me think about product work completely differently - every decision had to be intentional and judged with sensitivity.
Key achievements:
- Built a patient-support app under strict regulatory and ethical constraints
- Completed the full product lifecycle in 8 months, on time and on budget
- Managed stakeholders and negotiated a novel partnership model (later adopted by Amgen core business as an exemplar for innovation partnerships)
- Live pilot launched in Spain and France
Direct answers
- Worked with oncologists to reimagine patient care between appointments. Interviewed terminally ill patients.
- Dynamically spliced video to simulate personalised dermatology consultations for terminally ill cancer patients, designed for simplicity and trust.
- Led in-market discovery with patients, affiliates and HCPs, a new approach later adopted across their wider org. Negotiated a novel outcome-based partnership with Amgen.
- The Amgen relationship, Feb 2018 to Oct 2018 and after: a partnership project with the Amgen Commercial Business Unit; negotiated a novel outcome-based partnership; led in-market discovery & delivery; contract model & ways of working adopted as best practice across their org; Skincoach live & collecting user feedback as part of a closed pilot in Spain & France (Nov 2019). Troubleshooter for the CEO at UK2, 2008-2010[UK2].
- Distribution: Skincoach reached patients through Amgen, a partnership project with the Amgen Commercial Business Unit, with a live pilot in Spain and France; Wegovycare reached patients through Novo's market affiliates, co-created with markets and adopted by multiple markets[NOVO.R1]; the Wegovy Pill work was with the US affiliate on direct distribution[NOVO.R2.WEGOVY]; at UK2 a domain registration, management and reseller platform served B2B and B2C growth[UK2]; EuroDNS operated in both the B2B & B2C sectors[EURODNS].
source: Tom's own account, direct answers
Related
- Ask: what motivates you META.COMPASS
- LEO Innovation Lab: tell me about LEO LEO